Case Report: Immune Checkpoint Blockade Plus Interferon-Γ Add-On Antifungal Therapy in the Treatment of Refractory Covid-Associated Pulmonary Aspergillosis and Cerebral Mucormycosis

Invasive fungal diseases (IFD) still cause substantial morbidity and mortality, and new therapeutic approaches are urgently needed. Recent data suggest a benefit of checkpoint inhibitors (ICI). We report the case of a diabetic patient with refractory IFD following a SARSCoV-2 infection treated by IC...

Descripción completa

Detalles Bibliográficos
Autores principales: Serris, Alexandra, Ouedrani, Amani, Uhel, Fabrice, Gazzano, Marianne, Bedarida, Vincent, Rouzaud, Claire, Bougnoux, Marie-Elisabeth, Raphalen, Jean-Herlé, Poirée, Sylvain, Lambotte, Olivier, Martin-Blondel, Guillaume, Lanternier, Fanny
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9199385/
https://www.ncbi.nlm.nih.gov/pubmed/35720319
http://dx.doi.org/10.3389/fimmu.2022.900522
_version_ 1784727831688773632
author Serris, Alexandra
Ouedrani, Amani
Uhel, Fabrice
Gazzano, Marianne
Bedarida, Vincent
Rouzaud, Claire
Bougnoux, Marie-Elisabeth
Raphalen, Jean-Herlé
Poirée, Sylvain
Lambotte, Olivier
Martin-Blondel, Guillaume
Lanternier, Fanny
author_facet Serris, Alexandra
Ouedrani, Amani
Uhel, Fabrice
Gazzano, Marianne
Bedarida, Vincent
Rouzaud, Claire
Bougnoux, Marie-Elisabeth
Raphalen, Jean-Herlé
Poirée, Sylvain
Lambotte, Olivier
Martin-Blondel, Guillaume
Lanternier, Fanny
author_sort Serris, Alexandra
collection PubMed
description Invasive fungal diseases (IFD) still cause substantial morbidity and mortality, and new therapeutic approaches are urgently needed. Recent data suggest a benefit of checkpoint inhibitors (ICI). We report the case of a diabetic patient with refractory IFD following a SARSCoV-2 infection treated by ICI and interferon-gamma associated with antifungal treatment.
format Online
Article
Text
id pubmed-9199385
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91993852022-06-16 Case Report: Immune Checkpoint Blockade Plus Interferon-Γ Add-On Antifungal Therapy in the Treatment of Refractory Covid-Associated Pulmonary Aspergillosis and Cerebral Mucormycosis Serris, Alexandra Ouedrani, Amani Uhel, Fabrice Gazzano, Marianne Bedarida, Vincent Rouzaud, Claire Bougnoux, Marie-Elisabeth Raphalen, Jean-Herlé Poirée, Sylvain Lambotte, Olivier Martin-Blondel, Guillaume Lanternier, Fanny Front Immunol Immunology Invasive fungal diseases (IFD) still cause substantial morbidity and mortality, and new therapeutic approaches are urgently needed. Recent data suggest a benefit of checkpoint inhibitors (ICI). We report the case of a diabetic patient with refractory IFD following a SARSCoV-2 infection treated by ICI and interferon-gamma associated with antifungal treatment. Frontiers Media S.A. 2022-06-01 /pmc/articles/PMC9199385/ /pubmed/35720319 http://dx.doi.org/10.3389/fimmu.2022.900522 Text en Copyright © 2022 Serris, Ouedrani, Uhel, Gazzano, Bedarida, Rouzaud, Bougnoux, Raphalen, Poirée, Lambotte, Martin-Blondel and Lanternier https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Serris, Alexandra
Ouedrani, Amani
Uhel, Fabrice
Gazzano, Marianne
Bedarida, Vincent
Rouzaud, Claire
Bougnoux, Marie-Elisabeth
Raphalen, Jean-Herlé
Poirée, Sylvain
Lambotte, Olivier
Martin-Blondel, Guillaume
Lanternier, Fanny
Case Report: Immune Checkpoint Blockade Plus Interferon-Γ Add-On Antifungal Therapy in the Treatment of Refractory Covid-Associated Pulmonary Aspergillosis and Cerebral Mucormycosis
title Case Report: Immune Checkpoint Blockade Plus Interferon-Γ Add-On Antifungal Therapy in the Treatment of Refractory Covid-Associated Pulmonary Aspergillosis and Cerebral Mucormycosis
title_full Case Report: Immune Checkpoint Blockade Plus Interferon-Γ Add-On Antifungal Therapy in the Treatment of Refractory Covid-Associated Pulmonary Aspergillosis and Cerebral Mucormycosis
title_fullStr Case Report: Immune Checkpoint Blockade Plus Interferon-Γ Add-On Antifungal Therapy in the Treatment of Refractory Covid-Associated Pulmonary Aspergillosis and Cerebral Mucormycosis
title_full_unstemmed Case Report: Immune Checkpoint Blockade Plus Interferon-Γ Add-On Antifungal Therapy in the Treatment of Refractory Covid-Associated Pulmonary Aspergillosis and Cerebral Mucormycosis
title_short Case Report: Immune Checkpoint Blockade Plus Interferon-Γ Add-On Antifungal Therapy in the Treatment of Refractory Covid-Associated Pulmonary Aspergillosis and Cerebral Mucormycosis
title_sort case report: immune checkpoint blockade plus interferon-γ add-on antifungal therapy in the treatment of refractory covid-associated pulmonary aspergillosis and cerebral mucormycosis
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9199385/
https://www.ncbi.nlm.nih.gov/pubmed/35720319
http://dx.doi.org/10.3389/fimmu.2022.900522
work_keys_str_mv AT serrisalexandra casereportimmunecheckpointblockadeplusinterferongaddonantifungaltherapyinthetreatmentofrefractorycovidassociatedpulmonaryaspergillosisandcerebralmucormycosis
AT ouedraniamani casereportimmunecheckpointblockadeplusinterferongaddonantifungaltherapyinthetreatmentofrefractorycovidassociatedpulmonaryaspergillosisandcerebralmucormycosis
AT uhelfabrice casereportimmunecheckpointblockadeplusinterferongaddonantifungaltherapyinthetreatmentofrefractorycovidassociatedpulmonaryaspergillosisandcerebralmucormycosis
AT gazzanomarianne casereportimmunecheckpointblockadeplusinterferongaddonantifungaltherapyinthetreatmentofrefractorycovidassociatedpulmonaryaspergillosisandcerebralmucormycosis
AT bedaridavincent casereportimmunecheckpointblockadeplusinterferongaddonantifungaltherapyinthetreatmentofrefractorycovidassociatedpulmonaryaspergillosisandcerebralmucormycosis
AT rouzaudclaire casereportimmunecheckpointblockadeplusinterferongaddonantifungaltherapyinthetreatmentofrefractorycovidassociatedpulmonaryaspergillosisandcerebralmucormycosis
AT bougnouxmarieelisabeth casereportimmunecheckpointblockadeplusinterferongaddonantifungaltherapyinthetreatmentofrefractorycovidassociatedpulmonaryaspergillosisandcerebralmucormycosis
AT raphalenjeanherle casereportimmunecheckpointblockadeplusinterferongaddonantifungaltherapyinthetreatmentofrefractorycovidassociatedpulmonaryaspergillosisandcerebralmucormycosis
AT poireesylvain casereportimmunecheckpointblockadeplusinterferongaddonantifungaltherapyinthetreatmentofrefractorycovidassociatedpulmonaryaspergillosisandcerebralmucormycosis
AT lambotteolivier casereportimmunecheckpointblockadeplusinterferongaddonantifungaltherapyinthetreatmentofrefractorycovidassociatedpulmonaryaspergillosisandcerebralmucormycosis
AT martinblondelguillaume casereportimmunecheckpointblockadeplusinterferongaddonantifungaltherapyinthetreatmentofrefractorycovidassociatedpulmonaryaspergillosisandcerebralmucormycosis
AT lanternierfanny casereportimmunecheckpointblockadeplusinterferongaddonantifungaltherapyinthetreatmentofrefractorycovidassociatedpulmonaryaspergillosisandcerebralmucormycosis

Ejemplares similares